Oceanpine Capital

Oceanpine Capital is a growth equity investment firm founded in 2016 and headquartered in Hong Kong, with additional offices in Beijing, Shanghai, and San Francisco. The firm specializes in partnering with entrepreneurs to nurture early to late-stage companies, focusing on sectors such as technology, media, telecommunications, healthcare, and advanced manufacturing. Oceanpine Capital aims to invest in private companies exhibiting rapid growth potential, while also exploring select opportunities in public companies. The firm emphasizes innovation in areas like artificial intelligence, semiconductors, 5G, cloud computing, and biotech, providing strategic resources and operational support to help build long-term, world-class businesses.

David Liguang Chenn

CEO

Adam Sun

Founding Partner

43 past transactions

Xingchen New Energy

Seed Round in 2023
Xingchen New Energy develops new generation of ultra-high-performance all-vanadium flow energy storage system, fully covering electrolyte, stack and core R&D, manufacturing and production of components, energy storage systems and other products, and provide safer comprehensive energy storage solutions.

Blue Wave

Seed Round in 2023
Blue Wave is a producer of Industrial IoT and Internet of Vehicles chips.

Renxin Technology

Series A in 2023
Renxin Technology is an automotive chip design company. It provides competitive chip and system solutions for the industry and follows the evolution and development of automotive EE architecture.

Kuixin

Series A in 2023
Kuixin Technology specializes in the development of integrated circuits designed to address the challenges of computing power scaling and high-speed interconnection. The company offers a diverse range of products, including USB, PCIe, SATA, SerDes, MIPI, DDR, HDMI, DP, and HBM chipsets. These solutions cater to various applications, including data centers, artificial intelligence, consumer electronics, automotive technology, and the Internet of Things (IoT). By focusing on innovative circuitry, Kuixin aims to enhance performance and connectivity across multiple sectors.

SIRUI

Venture Round in 2022
SIRUI is an intelligent technology company that concentrates on the growth of strategic emerging industries and key core technologies such as semiconductor equipment and new display. Their products include atomic layer deposition coating equipment and thin-film electroluminescence displays. Its overseas technology research and development center will gradually conduct research, development, and industrialization of ALD and EL technology. It provides mature and leading ALD coating solutions for global customers in industrial coating applications such as semiconductors and optoelectronics, and it aids in the development of related industries such as semiconductors.

Qinghai Lihao

Series B in 2022
Qinghai Lihao specializes in the research, development, production, and sales of crystalline silicon, particularly for use in semiconductor materials. The company is dedicated to mass production of high-purity crystalline silicon, which supports the renewable energy sector and meets the demands of clients in the semiconductor industry. By focusing on process technology, Qinghai Lihao aims to advance its capabilities in the new energy business while ensuring the availability of essential materials for various applications.

Enflame

Series C in 2022
Enflame specializes in developing high-end chips for artificial intelligence applications. Its products are designed for cloud data centers and optimized for AI training platforms. The company's offerings feature high computing power, energy efficiency, programmability, and compatibility with mainstream machine learning frameworks.

Huachen Core Light

Angel Round in 2022
Huachen Core Light is a semiconductor technology company that produces and manufactures optical communications and laser chips.

Aqronos

Series A in 2022
Aqronos is a technology company that specializes in the development of advanced LiDAR sensors aimed at enhancing autonomous driving and driver assistance systems. Their innovative solutions provide vehicles with exceptional vision capabilities, effectively transforming them into guardians on the road. By utilizing cutting-edge LiDAR technology, Aqronos aims to improve safety for drivers and passengers alike, ensuring a more secure driving experience.

Shenzhen Shifeng

Series A in 2022
Shenzhen Shifeng offers industrial software, digital twin systems, and a simulation cloud service platform. The company serves marine engineering, aerospace, energy, electronic appliances, car traffic, and engineering manufacturing.

Clounix

Series A in 2022
Clounix is a hardware and software company that develops high-performance programmable networking solutions for cloud-native data centers and telecommunications infrastructure. The company designs Ethernet switch chips and integrated networking hardware with customizable silicon architectures, support for open-source network operating systems, and compatibility with software-defined networking protocols. Its offerings enable internet service providers, enterprises, and cloud operators to build scalable, flexible, and secure next-generation networks and data centers, emphasizing low latency and ultra-high speed within cloud-native ecosystems.

Lisuan Technology

Angel Round in 2022
Liansu Technology is a software company specializing in the development of high-performance graphics rendering GPUs. The company focuses on creating domestically-made GPU chips using self-developed architecture and proprietary intellectual property. Liansu aims to serve the expansive domestic market for rendering GPUs, which is valued at 200 billion, by delivering high-performance graphics rendering solutions across various platforms, including devices, cloud computing, and automotive applications. Its products cater to diverse industries such as gaming, digital twins, the metaverse, virtual and augmented reality, ultra-high-definition video, and professional design. By leveraging its advanced technology, Liansu Technology provides partners with comprehensive software and hardware solutions tailored to meet the evolving needs of the digital economy.

OrthoGuard

Series A in 2021
OrthoGuard Physicians is a comprehensive orthopedic medical service organization based in China, focusing on the treatment and diagnosis of various musculoskeletal conditions, including joint, spine, ankle, and trauma injuries. The company emphasizes efficient management and innovative operational models to enhance patient care, facilitating quicker healing and improved recovery experiences. In addition to direct medical services, OrthoGuard is involved in hospital management, rehabilitation services, and education and training initiatives. The organization also engages in supply chain management and the establishment of demonstration diagnosis and treatment centers, aiming to create a reputable and innovative medical group in the orthopedic field. Through these efforts, OrthoGuard seeks to leverage its extensive resources and expertise to advance orthopedic healthcare in China.

Yuchuang Semiconductor

Series A in 2021
Erised Semiconductor is a circuit designer and manufacturer that provides users with display driver and power management chips. The applications can be found in radiofrequency applications, discrete devices, and other products.

Chipone Technology

Series E in 2021
Chipone Technology designs display chips for mobile, panel and LED displays, offering a broad range of solutions such as display driver and touch integrated chips (TDDI), medium and large-size display driver chips (LDDI), OLED display chips, power management chips, LED display drivers, timing controllers (Tcon), fingerprint sensing ICs, and related touch and display control components. The products are used across smartphones, TVs, laptops, tablets, wearables and various indoor and outdoor LED displays, with customers including global panel manufacturers and leading mobile brands.

MingMed

Series A in 2021
MingMed is a Chinese pharmaceutical company focused on independent drug research and development, demonstrating strong global competitiveness. The company specializes in a diverse product pipeline that includes ophthalmic drugs, recombinant protein botulinum toxin, tumor immune drugs, and immune therapies for pets. MingMed also emphasizes innovation, with several potential First-in-Class drugs currently in the clinical stage. Its research spans various therapeutic areas, delivering cutting-edge solutions in ophthalmology, medical aesthetics, and veterinary medicine, particularly through small molecule immune drugs and gene editing-based cell therapies.

SVOLT

Series B in 2021
SVOLT specializes in the manufacturing of electric vehicle batteries. Their product portfolio includes automotive power batteries and energy storage systems, catering to passenger cars, commercial vehicles, and energy storage markets.

Tongshu Gene

Series C in 2021
Tongshu Gene is a high-tech enterprise specializing in tumor precision medicine. The company offers gene testing services and develops advanced diagnostic molecular pathology projects, as well as ctDNA precision detection systems. Utilizing high-throughput gene sequencing technology and biological information analysis, Tongshu Gene aims to enhance clinical decision-making by providing consulting services that include precision medication, efficacy monitoring, postoperative recurrence monitoring, risk prediction, and early detection of tumors. Through its innovative approach, the company supports clinicians in improving patient outcomes in cancer treatment and management.

Stemirna

Venture Round in 2021
Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.

Weilong Foods

Series A in 2021
Weilong Foods is a prominent snack food brand based in Luohe, Henan Province, China, specializing in the production and sale of spicy snack foods. Founded in 1999 by Liu Weiping and Liu Fuping, the company operates through various business units categorized into three main segments: seasoned flour products, vegetable products, and bean-based and other products. The seasoned flour products, which include items like Big Latiao and Spicy Hot Stick, generate the majority of the company's revenue. In addition to these, Weilong Foods also offers products such as Konjac Shuang and Soft Tofu Skin, catering to a diverse consumer base within the Chinese market.

Hepagene Therapeutics

Series B in 2021
Hepagene Therapeutics is a biopharmaceutical company focused on developing innovative treatments for liver diseases. The company is dedicated to researching and creating therapies for conditions such as non-alcoholic steatohepatitis (NASH), chronic Hepatitis B infection, and liver cancer. Hepagene Therapeutics aims to address the significant unmet medical needs in the field of hepatology, striving to improve patient outcomes through its targeted drug development efforts.

TechnoDerma Medicines

Series A in 2021
TechnoDerma Medicines is a private clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for various skin diseases. The company focuses on creating small molecular drugs aimed at treating conditions such as androgenetic alopecia, atopic dermatitis, psoriasis, lupus erythematosus, and scars. By prioritizing research and development, TechnoDerma Medicines seeks to provide patients with safe and effective treatment options to improve their quality of life and address unmet medical needs in dermatological care.

Immune-Onc Therapeutics

Series B in 2021
Founded in 2016, Immune-Onc Therapeutics is a biopharmaceutical company dedicated to developing innovative biologics for cancer treatment. The company translates scientific insights into the tumor microenvironment and immune suppressive pathways to create novel therapeutics.

JuLive.com

Series C in 2021
Julive is a new house transaction service platform.

LakeShore Biopharma

Series B in 2021
Yisheng Biopharma Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of immuno-oncology products and vaccines. Founded in 2002 and headquartered in Beijing, the company operates in China, the United States, Cambodia, and Singapore. Yisheng Biopharma utilizes its novel PIKA immunomodulating technology to enhance immune responses against cancers and infectious diseases. Key products under development include YS-ON-001, an investigational therapy aimed at treating advanced solid tumors, as well as YS-HBV-001, a vaccine for hepatitis B, and a PIKA-based rabies vaccine designed for rapid protection against rabies infection. The company's innovative approach targets multiple immune pathways to improve treatment outcomes.

Teon Therapeutics

Series A in 2021
Teon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Redwood, California, focused on advancing cancer immunotherapy. Founded in 2018, the company specializes in the discovery and development of small molecule drugs aimed at inhibiting immunosuppressive and cancer-promoting signaling pathways within the tumor microenvironment. Teon Therapeutics is dedicated to improving the lives of cancer patients by developing a targeted portfolio of molecules that not only restore antitumor immunity but also suppress cancer cell proliferation. Their lead program involves an A2BR-specific antagonist that is set to enter Phase 1b clinical trials. By integrating metabolic checkpoint inhibitors and GPCR immune checkpoint inhibitors, Teon aims to enhance the efficacy of existing immunotherapies and improve long-term outcomes for cancer patients.

Clover Biopharmaceuticals

Series C in 2021
Clover Biopharmaceuticals, established in 2016, is a global, clinical-stage biotech company dedicated to discovering, developing, and commercializing innovative biologics targeting trimerization-dependent pathways in oncology and autoimmune diseases. The company's proprietary Trimer-Tag© technology platform enables the creation of novel biologics. Additionally, Clover employs its in-house cGMP biomanufacturing capabilities for select biosimilars development.

Sinovent

Venture Round in 2020
Sinovent, established in 2016, is a global biopharmaceutical company with headquarters in Suzhou, China, and offices in Beijing, China, and Boston, U.S.A. It specializes in developing advanced treatments for global healthcare challenges, with a focus on oncology, autoimmune diseases, and infectious diseases. Sinovent's portfolio comprises 12 products in various stages of development, leveraging its expertise in science, management, and finance to deliver innovative solutions to patients worldwide.

XtalPi

Series C in 2020
XtalPi is a pharmaceutical technology company that applies quantum mechanics, artificial intelligence, and high-performance computing to accelerate drug discovery and development. Its Intelligent Digital Drug Discovery and Development platform weaves physics-based modeling with AI to increase efficiency, accuracy, and success rates at critical stages of R&D. The company offers tools for crystal structure prediction and determination, solid-state testing and analysis, and crystallization process development, as well as solid-state screening and evaluation, enabling faster optimization of drug candidates. XtalPi also provides drug design support for small molecules and collaboration options in antibody and peptide research, and offers platform-based AI model development and integration across pharmaceutical workflows. Founded in 2014, it is based in Cambridge, Massachusetts, with additional offices in China.

Guangzhou Creative Biosciences

Series C in 2020
Guangzhou Creative Biosciences, established in Guangzhou, China, specializes in the research, development, production, and sales of diagnostic kits for colorectal cancer screening. Their primary product is a non-invasive fecal DNA screening kit, which enables early detection of colorectal cancer by interpreting genetic abnormalities in feces. Additionally, the company offers diagnostic kits and equipment for lung cancer.

Triumvira Immunologics

Series A in 2020
Triumvira Immunologics USA, Inc. is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies aimed at improving cancer treatment outcomes. Its primary offerings include chimeric antigen receptor (CAR) therapies and engineered T cell receptor (TCR) therapies. A key aspect of Triumvira's approach is its proprietary T cell Antigen Coupler (TAC) technology, which recruits the entire natural T cell receptor and operates independently of the major histocompatibility complex (MHC). This technology enables the development of more effective therapies for a wider array of patients suffering from both solid and liquid malignancies, as well as other diseases beyond cancer.

Sinovent

Series C in 2020
Sinovent, established in 2016, is a global biopharmaceutical company with headquarters in Suzhou, China, and offices in Beijing, China, and Boston, U.S.A. It specializes in developing advanced treatments for global healthcare challenges, with a focus on oncology, autoimmune diseases, and infectious diseases. Sinovent's portfolio comprises 12 products in various stages of development, leveraging its expertise in science, management, and finance to deliver innovative solutions to patients worldwide.

HireEZ

Series B in 2020
HireEZ is a provider of an AI-powered outbound recruiting platform that helps recruiters shift from inbound to outbound strategies. The platform offers market insights and talent visibility to enable organizations to identify and engage the right candidates, scale their recruitment efforts, and build a workforce for the future. By making outbound recruiting more strategic and scalable, HireEZ supports efforts to create more inclusive workplaces and improve hiring outcomes.

Enflame

Series B in 2020
Enflame specializes in developing high-end chips for artificial intelligence applications. Its products are designed for cloud data centers and optimized for AI training platforms. The company's offerings feature high computing power, energy efficiency, programmability, and compatibility with mainstream machine learning frameworks.

Apexigen

Series C in 2020
Apexigen Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, focused on developing antibody therapeutics for cancer treatment. Established in 2010, Apexigen specializes in immuno-oncology, creating therapies that aim to leverage the patient's immune system to effectively combat and eradicate cancer. The company's pipeline includes several promising candidates, such as APX005M and APX201 for immuno-oncology, along with additional programs targeting various oncology and inflammation conditions. Notably, its lead candidate, sotigalimab, is currently in clinical development, complemented by a range of preclinical immuno-oncology programs. Apexigen also utilizes its proprietary APXiMAB platform to discover novel antibodies targeting immune system pathways, underscoring its commitment to advancing innovative treatments in cancer care.

Zshield

Series B in 2019
Zshield Inc. is a Beijing-based company specializing in cyberspace data security and big data business risk management. Established in 2014, it is recognized as the first high-tech firm in China to leverage big data technologies in addressing emerging information security vulnerabilities. Zshield develops advanced integrated information security solutions that utilize lightweight virtualization, deep learning, and big data analysis to provide effective monitoring of server and terminal security. Its offerings include a comprehensive information security platform and the AndunTM ZS-ISP, which supports both government and enterprise clients in navigating the complexities of modern computing environments, including cloud computing and mobile applications. As traditional security measures struggle to cope with new threats, Zshield's innovative approach aims to fortify businesses against the evolving landscape of information security challenges.

Ansun Biopharma

Series B in 2019
Ansun Biopharma is a clinical-stage biopharmaceutical company based in San Diego that develops host-directed anti-viral therapies to prevent and treat life-threatening respiratory infections. The company focuses on therapies targeting the host rather than the virus, aiming to overcome viral mutation and immune evasion. Its pipeline includes Fludase, candidate for prophylaxis and treatment of influenza and parainfluenza infections, and Viradin, an intravenous therapy for sepsis, septic shock, and certain viral hemorrhagic fevers. It also advances TOSAP formulation technology to create microspheres and nanospheres for drug delivery. Through these programs, Ansun Biopharma seeks to provide therapies for severe viral diseases where traditional antivirals face limitations.

Enflame

Series A in 2019
Enflame specializes in developing high-end chips for artificial intelligence applications. Its products are designed for cloud data centers and optimized for AI training platforms. The company's offerings feature high computing power, energy efficiency, programmability, and compatibility with mainstream machine learning frameworks.

Horizon Robotics

Series B in 2019
Horizon Robotics specializes in advanced driver-assistance systems (ADAS) and autonomous driving (AD) solutions for passenger vehicles. The company's offerings combine innovative algorithms, tailored software, and high-performance hardware to enhance safety and driving experience.

Inspirna

Series C in 2018
Inspirna is a clinical-stage biopharmaceutical company focused on developing first-in-class cancer therapies that target RNA-regulated drivers of tumor growth. Using RNA biology-based discovery platforms, including miRNA-DRIVEr and RNA-DRIVEr, it identifies novel cancer targets and advances them with oral small-molecule medicines and antibody-drug conjugates. Its lead programs include RGX-202 for RAS-mutant colorectal cancer and RGX-104 for small cell and non-small cell lung cancers, currently in early-phase trials (Phase 1b/2). The company aims to translate RNA-centric targets into treatments for patients with cancers that lack effective options.

51Zhaoyou.com

Series C in 2018
51Zhaoyou.com operates as a B2B ecommerce platform dedicated to the petroleum industry in China. It facilitates transactions through an online marketplace, offering comprehensive services including fuel trading, logistics management, and financial solutions tailored for its client base comprising leading logistics companies.

Tiger Brokers

Series C in 2018
Tiger Brokers is a financial services company founded in 2014 and headquartered in Singapore. It operates as an online brokerage focused on global investing and provides a range of services that include brokerage, employee stock ownership plan management, wealth management, investor education, and an investor community. In addition to retail trading, the firm offers corporate finance capabilities such as private investments in public equity, public investments, secondary offerings, reverse mergers, initial public offerings, mergers and acquisitions, and other advisory services. The company serves clients across technology and growth sectors, including cybersecurity, blockchain, mobile, edtech, manufacturing, the internet of things, clean tech, health tech, and information technology. By combining trading execution with investment banking and related financial services, Tiger Brokers aims to support investors and corporations in accessing global markets with a comprehensive suite of tools and resources.

Ansun Biopharma

Series A in 2018
Ansun Biopharma is a clinical-stage biopharmaceutical company based in San Diego that develops host-directed anti-viral therapies to prevent and treat life-threatening respiratory infections. The company focuses on therapies targeting the host rather than the virus, aiming to overcome viral mutation and immune evasion. Its pipeline includes Fludase, candidate for prophylaxis and treatment of influenza and parainfluenza infections, and Viradin, an intravenous therapy for sepsis, septic shock, and certain viral hemorrhagic fevers. It also advances TOSAP formulation technology to create microspheres and nanospheres for drug delivery. Through these programs, Ansun Biopharma seeks to provide therapies for severe viral diseases where traditional antivirals face limitations.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.